Tandem Diabetes Posts 10-Cent Loss Per Share in Third Quarter
TNDM sits 47% above its 52-week low of $12.26.
Summary
Tandem Diabetes Care reported a third-quarter loss of 10 cents per share, per Dow Jones Newswires, amounting to a loss of $7.09 million. That follows a Q2 where sales rose 6% to $254.6 million and the net loss narrowed to $21.2 million, with gross margin at 57%. The company reported its Q3 2026 results and reaffirmed its guidance. The headline gives only the bottom line, so the key read-throughs — revenue growth, margin, and pump demand — are not yet in hand. The stock trades near $18 against a small-cap valuation, so a loss print of this size keeps profitability timing in question. Full quarterly detail, including sales and guidance, will determine whether this is a modest miss or a real deterioration.
At the time of this announcement, TNDM was trading at $17.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $12.26 to $29.65. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.